Institutional members access full text with Ovid®

Share this article on:

HIV escape and attenuation by cytotoxic T lymphocytes

Leslie, Alasdair Ja; Goulder, Philip JRa,b

Current Opinion in HIV and AIDS: January 2006 - Volume 1 - Issue 1 - p 34–39
doi: 10.1097/01.COH.0000194102.28063.7c
The T cell in HIV infection and disease: Basic science

Purpose of review Much of the current HIV-1 vaccine research focuses on harnessing the cytotoxic T-lymphocyte arm of the immune response. However, HIV-1 appears to have an unerring ability to evade cytotoxic T-lymphocyte responses, through the process of escape mutation, and thus the potential benefit of a cytotoxic T-lymphocyte-based vaccine remains uncertain. This review focuses on several recent studies that question whether escape mutation is always detrimental to the host, and may provide new hope for the success of a cytotoxic T-lymphocyte-based vaccine against HIV.

Recent findings Several recent studies, in both natural HIV-1 infection and the SIV model, have identified examples of cytotoxic T-lymphocyte escape mutants that revert on transmission to individuals lacking the selecting major histocompatibility complex alleles. The obvious implication of these data is that some cytotoxic T-lymphocyte responses can only be evaded through escape mutations that actually reduce the replicative fitness of the virus. In addition, a recent vaccine study in macaques found that the control of immunodeficiency virus to undetectable levels was only achieved in animals that were able to force the virus to make such detrimental escape mutations. These data raise the intriguing possibility that, rather than undermining cytotoxic T-lymphocyte vaccines, escape mutation may be one of the keys to their success.

Summary Clearly, not all escape mutations help to control viral replication. We discuss how these new data may assist in the struggle to develop a successful cytotoxic T-lymphocyte-based HIV vaccine, and what they tell us about the responses such a vaccine should aim to elicit.

aDepartment of Pediatrics, Nuffield Department of Medicine, University of Oxford, Oxford, UK

bPartners AIDS Research Center and Harvard Medical School, Boston, Massachusetts, USA

Correspondence to Philip J.R. Goulder, Department of Pediatrics, Nuffield Department of Medicine, Peter Medawar Building for Pathogen Research, University of Oxford, Oxford OX1 3SY, UK E-mail: philip.goulder@ndm.ox.ac.uk

© 2006 Lippincott Williams & Wilkins, Inc.